A Phase 3 interventional study of Mirikizumab in Crohn's Disease, sponsored by Eli Lilly and Company. Recruiting at 81 sites in 16 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mirikizumab in Crohn Disease — 7 open to participants now, 8 under way, 3 of them phase 3. mirikizumab · Crohn Disease.
Among the 10 studies testing mirikizumab in Crohn Disease, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 4 in phase 3, and was the 5th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →7 of the 10 studies testing mirikizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18–75
Alimentiv Inc. · Sites in United States, Canada
Ages 18+
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 90 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 150 across the 10 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
10 studies in Crohn Disease by Eli Lilly and Company: 6 open now, 7 under way, 4 of them phase 3. Of 3 finished, 2 (67%) have results posted.
Among the 10 studies in Crohn Disease by Eli Lilly and Company, this one is the 8th largest by planned enrollment, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 5th registered.
Eli Lilly and Company’s Crohn Disease studies by the year they started, since 2016.
2 of the studies testing mirikizumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06997965Alimentiv Inc.Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD | 2027-09-01 |
| NCT07292012Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesEfficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing mirikizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 10 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.
Study periods for the intervention-specific appendix (ISA) will be as follows:
The study will last about 74 weeks and may include up to 19 visits.
Participants screened in the MACARONI-23 Platform study could be randomized to mirikizumab to participate in this intervention specific arm of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mirikizumab administered intravenously (IV) or subcutaneously (SC) in participants that weigh greater than (\>) 40 kilograms (kg).
Drug: Mirikizumab
Mirikizumab administered IV or SC in participants that weigh \>20 kg to less than or equal to (≤) 40 kg. Dosing is based on assessments of the participant's weight and appropriate weight class.
Drug: Mirikizumab
Mirikizumab administered IV or SC in participants that weigh greater than or equal to (≥) 9 kg to less than or equal to ≤20 kg. Dosing is based on assessments of the participant's weight and appropriate weight class.
Drug: Mirikizumab
Administered IV or SC
Also known as: LY3074828
Percentage of Participants with Clinical Response by Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and Endoscopic Response by Simple Endoscopic Score for CD (SES-CD) at Week 52
Clinical response based on PCDAI, and endoscopic response based on SES-CD.
Time frame: Baseline to Week 52
Percentage of Participants with a Clinical Response by PCDAI at Week 12 and Clinical Remission by PCDAI at Week 52
Clinical response based on PCDAI, and clinical remission based on PCDAI.
Time frame: Baseline to Week 52
Percentage of Participants Achieving Clinical Response by PCDAI
Clinical response based on PCDAI.
Time frame: Week 12
Percentage of Participants Achieving Clinical Response by Clinical Disease Activity Index (CDAI)
Clinical response based on CDAI for participants ≥12 years of age
Time frame: Week 12
Percentage of Participants Achieving Clinical Remission by PCDAI
Clinical remission based on PCDAI.
Time frame: Week 12
Percentage of Participants Achieving Clinical Remission by CDAI
Clinical remission based on CDAI for participants ≥12 years of age.
Time frame: Week 12
Percentage of Participants Who Achieve PCDAI Clinical Response at Week 12 and PCDAI Clinical Remission and Endoscopic Remission at Week 52
Time frame: Baseline to Week 52
Percentage of Participants Who Achieve PCDAI Clinical Remission and Endoscopic Remission at Week 52
Time frame: Week 52
Percentage of Participants Achieving Clinical Response by PCDAI at Week 12 and Endoscopic Remission by SES-CD at Week 52
Time frame: Baseline to Week 52
Change from Baseline in C-reactive Protein (CRP)
Time frame: Baseline, Week 12
Change from Baseline in CRP
Time frame: Baseline, Week 52
Change from Baseline in Fecal calprotectin
Time frame: Baseline, Week 12
Change from Baseline in Fecal calprotectin
Time frame: Baseline, Week 52
Percentage of Participants Achieving Clinical Response PCDAI at Week 12 and Clinical Remission by CDAI at Week 52
Clinical response by PCDAI, CDAI for participants ≥12 years of age
Time frame: Baseline to Week 52
Percentage of Participants Achieving Endoscopic Response
Time frame: Week 52
Percentage of Participants Achieving Clinical Remission by PCDAI
Clinical remission based on PCDAI
Time frame: Week 52
Percentage of Participants Achieving Clinical Response by PCDAI at Week 12 and PCDAI Clinical Remission without the use of Corticosteroids and Who Did Not Have Crohn's Disease (CD)-Related Surgery at Week 52
Clinical response and clinical remission by PCDAI
Time frame: Baseline to Week 52
Pharmacokinetics (PK): Clearance of Mirikizumab
Time frame: Baseline through Week 52
Pharmacokinetics (PK): Volume of Distribution of Mirikizumab
Time frame: Baseline through Week 52
Not enrolling at this site — choose another above.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's planned 45 months is close to that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab